Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months

G. C. Yee, T. R. McGuire, B. A. St Pierre, S. G. Self, R. A. Zager, K. M. Sullivan, H. J. Deeg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To determine whether 6 months of cyclosporine therapy is associated with chronic renal dysfunction, we evaluated serum creatinine concentrations 1 year post-transplant in 82 marrow transplant recipients randomized to receive either cyclosporine (n = 40) or methotrexate (n = 42) as graft-versus-host disease (GVHD) prophylaxis. Nine patients in the methotrexate group were later given cyclosporine as treatment for acute or chronic GVHD (methotrexate → cyclosporine). Cyclosporine prophylaxis was started on the day before marrow infusion, given at full doses until day 50, then gradually tapered and discontinued by day 180. Methotrexate prophylaxis was started on day 1 and given intermittently until day 102. Patients in the cyclosporine and methotrexate → cyclosporine groups had significantly higher mean serum creatinine values during the first 100 days post-transplant than methotrexate-treated patients, but by 1 year mean serum creatinine values were not significantly different between the three groups. Serum creatinine values at 1 year were also not significantly different from baseline values in each of the groups. None of the patients who had their cyclosporine discontinued by day 180 developed chronic renal dysfunction, defined as a doubling of the baseline serum creatinine at 1 year. We conclude that chronic renal dysfunction occurs rarely in marrow transplant recipients treated with 6 months of cyclosporine and when it does occur, it appears to have minimal clinical significance.

Original languageEnglish (US)
Pages (from-to)691-694
Number of pages4
JournalBone marrow transplantation
Volume4
Issue number6
StatePublished - Dec 1 1989

Fingerprint

Cyclosporine
Bone Marrow
Kidney
Methotrexate
Creatinine
Serum
Graft vs Host Disease
Transplants
Transplant Recipients
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. / Yee, G. C.; McGuire, T. R.; St Pierre, B. A.; Self, S. G.; Zager, R. A.; Sullivan, K. M.; Deeg, H. J.

In: Bone marrow transplantation, Vol. 4, No. 6, 01.12.1989, p. 691-694.

Research output: Contribution to journalArticle

Yee, G. C. ; McGuire, T. R. ; St Pierre, B. A. ; Self, S. G. ; Zager, R. A. ; Sullivan, K. M. ; Deeg, H. J. / Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. In: Bone marrow transplantation. 1989 ; Vol. 4, No. 6. pp. 691-694.
@article{82cf46cd26df4ba3bd5b590d03286a76,
title = "Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months",
abstract = "To determine whether 6 months of cyclosporine therapy is associated with chronic renal dysfunction, we evaluated serum creatinine concentrations 1 year post-transplant in 82 marrow transplant recipients randomized to receive either cyclosporine (n = 40) or methotrexate (n = 42) as graft-versus-host disease (GVHD) prophylaxis. Nine patients in the methotrexate group were later given cyclosporine as treatment for acute or chronic GVHD (methotrexate → cyclosporine). Cyclosporine prophylaxis was started on the day before marrow infusion, given at full doses until day 50, then gradually tapered and discontinued by day 180. Methotrexate prophylaxis was started on day 1 and given intermittently until day 102. Patients in the cyclosporine and methotrexate → cyclosporine groups had significantly higher mean serum creatinine values during the first 100 days post-transplant than methotrexate-treated patients, but by 1 year mean serum creatinine values were not significantly different between the three groups. Serum creatinine values at 1 year were also not significantly different from baseline values in each of the groups. None of the patients who had their cyclosporine discontinued by day 180 developed chronic renal dysfunction, defined as a doubling of the baseline serum creatinine at 1 year. We conclude that chronic renal dysfunction occurs rarely in marrow transplant recipients treated with 6 months of cyclosporine and when it does occur, it appears to have minimal clinical significance.",
author = "Yee, {G. C.} and McGuire, {T. R.} and {St Pierre}, {B. A.} and Self, {S. G.} and Zager, {R. A.} and Sullivan, {K. M.} and Deeg, {H. J.}",
year = "1989",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "691--694",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months

AU - Yee, G. C.

AU - McGuire, T. R.

AU - St Pierre, B. A.

AU - Self, S. G.

AU - Zager, R. A.

AU - Sullivan, K. M.

AU - Deeg, H. J.

PY - 1989/12/1

Y1 - 1989/12/1

N2 - To determine whether 6 months of cyclosporine therapy is associated with chronic renal dysfunction, we evaluated serum creatinine concentrations 1 year post-transplant in 82 marrow transplant recipients randomized to receive either cyclosporine (n = 40) or methotrexate (n = 42) as graft-versus-host disease (GVHD) prophylaxis. Nine patients in the methotrexate group were later given cyclosporine as treatment for acute or chronic GVHD (methotrexate → cyclosporine). Cyclosporine prophylaxis was started on the day before marrow infusion, given at full doses until day 50, then gradually tapered and discontinued by day 180. Methotrexate prophylaxis was started on day 1 and given intermittently until day 102. Patients in the cyclosporine and methotrexate → cyclosporine groups had significantly higher mean serum creatinine values during the first 100 days post-transplant than methotrexate-treated patients, but by 1 year mean serum creatinine values were not significantly different between the three groups. Serum creatinine values at 1 year were also not significantly different from baseline values in each of the groups. None of the patients who had their cyclosporine discontinued by day 180 developed chronic renal dysfunction, defined as a doubling of the baseline serum creatinine at 1 year. We conclude that chronic renal dysfunction occurs rarely in marrow transplant recipients treated with 6 months of cyclosporine and when it does occur, it appears to have minimal clinical significance.

AB - To determine whether 6 months of cyclosporine therapy is associated with chronic renal dysfunction, we evaluated serum creatinine concentrations 1 year post-transplant in 82 marrow transplant recipients randomized to receive either cyclosporine (n = 40) or methotrexate (n = 42) as graft-versus-host disease (GVHD) prophylaxis. Nine patients in the methotrexate group were later given cyclosporine as treatment for acute or chronic GVHD (methotrexate → cyclosporine). Cyclosporine prophylaxis was started on the day before marrow infusion, given at full doses until day 50, then gradually tapered and discontinued by day 180. Methotrexate prophylaxis was started on day 1 and given intermittently until day 102. Patients in the cyclosporine and methotrexate → cyclosporine groups had significantly higher mean serum creatinine values during the first 100 days post-transplant than methotrexate-treated patients, but by 1 year mean serum creatinine values were not significantly different between the three groups. Serum creatinine values at 1 year were also not significantly different from baseline values in each of the groups. None of the patients who had their cyclosporine discontinued by day 180 developed chronic renal dysfunction, defined as a doubling of the baseline serum creatinine at 1 year. We conclude that chronic renal dysfunction occurs rarely in marrow transplant recipients treated with 6 months of cyclosporine and when it does occur, it appears to have minimal clinical significance.

UR - http://www.scopus.com/inward/record.url?scp=0024791772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024791772&partnerID=8YFLogxK

M3 - Article

C2 - 2684309

AN - SCOPUS:0024791772

VL - 4

SP - 691

EP - 694

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -